Literature DB >> 16733518

Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q.

K A White1, E M Lange, A M Ray, K J Wojno, K A Cooney.   

Abstract

BACKGROUND: Linkage studies have provided evidence for a prostate cancer susceptibility locus on chromosome 17q. The mitochondrial protein prohibitin (PHB) is a plausible candidate gene based on its chromosomal location (17q21) and known function.
METHODS: All coding regions and intron/exon junctions of the PHB gene were sequenced in 32 men from families participating in the University of Michigan Prostate Cancer Genetics Project that demonstrated evidence of linkage to 17q markers.
RESULTS: Although a number of nucleotide variants were identified, no coding region substitutions were identified in any of the 32 men with prostate cancer from 32 unrelated multiplex prostate cancer families.
CONCLUSIONS: PHB mutations do not appear to account for the linkage signal on 17q21-22 detected in PCGP families. Fine mapping of this region is in progress to refine the candidate region and highlight additional candidate prostate cancer susceptibility genes for sequence analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733518     DOI: 10.1038/sj.pcan.4500878

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  2 in total

1.  Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis.

Authors:  Ethan M Lange; Christiane M Robbins; Elizabeth M Gillanders; Siqun Lilly Zheng; Jianfeng Xu; Yunfei Wang; Kirsten A White; Bao-Li Chang; Lindsey A Ho; Jeffrey M Trent; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  Hum Genet       Date:  2006-11-21       Impact factor: 4.132

2.  Association of 17q24 rs1859962 gene polymorphism with prostate cancer risk: A systematic review and meta-analysis.

Authors:  Feiqiang Ren; Peihai Zhang; Ziyang Ma; Ling Zhang; Guangsen Li; Xiaopeng Huang; Degui Chang; Xujun Yu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.